ARCHIVES

FDA, ASCO Meet to Review Drug Approval Endpoints

This article is from The Cancer Letter archive.

Vol. 29 No. 17 | April 25, 2003

Download PDF Visit The Full Archive

Related Articles

NIH Policy On Diversity In Sponsored Meetings

June 16, 1995

CPRU Program Gets Basic Concept Approval

October 2, 1987

UCSD Cancer Center Breaks Ground for New Building

November 15, 2002

NCAB Considers Discrimination Against Patients, Minority Rates, Smokeless Tobacco

April 12, 1985

In Brief: NCAB Committee Worried About Requirements for Comprehensive Centers, To Meet Again

May 27, 1988

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

December 17, 2013